Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Rating of “Buy” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned a consensus rating of “Buy” from the eighteen analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $335.13.

ILMN has been the subject of several recent analyst reports. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and set a $355.00 price objective for the company in a research note on Friday, January 3rd. ValuEngine lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, December 20th. Credit Suisse Group reaffirmed a “buy” rating and set a $340.00 price objective on shares of Illumina in a research note on Tuesday, February 4th. Piper Sandler lifted their price objective on shares of Illumina from $341.00 to $370.00 and gave the stock an “overweight” rating in a research note on Thursday, January 9th. Finally, Zacks Investment Research lowered shares of Illumina from a “hold” rating to a “sell” rating and set a $341.00 price objective for the company. in a research note on Monday, January 20th.

NASDAQ ILMN traded up $7.54 on Friday, reaching $298.92. 1,494,621 shares of the stock were exchanged. Illumina has a one year low of $263.30 and a one year high of $380.76. The company’s 50-day simple moving average is $316.61 and its two-hundred day simple moving average is $305.87.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Wednesday, January 29th. The life sciences company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.12. The company had revenue of $953.00 million for the quarter, compared to the consensus estimate of $950.16 million. The company’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 EPS. Sell-side analysts forecast that Illumina will post 6.86 EPS for the current year.

In other news, CFO Sam Samad sold 892 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $320.00, for a total transaction of $285,440.00. Following the completion of the sale, the chief financial officer now directly owns 3,461 shares of the company’s stock, valued at $1,107,520. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Susan H. Tousi sold 200 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $325.00, for a total transaction of $65,000.00. Following the sale, the senior vice president now directly owns 38,465 shares of the company’s stock, valued at $12,501,125. The disclosure for this sale can be found here. Insiders have sold 4,197 shares of company stock valued at $1,345,987 over the last three months. Insiders own 0.38% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ILMN. Princeton Global Asset Management LLC bought a new stake in shares of Illumina in the fourth quarter valued at about $25,000. Credit Agricole S A bought a new stake in shares of Illumina in the fourth quarter valued at about $28,000. Savior LLC bought a new stake in shares of Illumina in the fourth quarter valued at about $31,000. Americana Partners LLC bought a new stake in shares of Illumina in the fourth quarter valued at about $37,000. Finally, Trust Co. of Vermont raised its holdings in shares of Illumina by 296.8% in the third quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 92 shares in the last quarter. 91.80% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: Why do commodities matter?

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit